Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose NUI Galway as their University of choice. Find out what life at NUI Galway is all about here.
About NUI Galway
About NUI Galway
Since 1845, NUI Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
NUI Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
- Business & Industry
- Alumni, Friends & Supporters
At NUI Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
November 2016 Good drugs for bad bugs: Simple changes to antibiotic treatment of MRSA may help beat the bacteria
- 20% of patients infected with MRSA are dying from systemic infections
- Antimicrobial resistance infections are projected to cause more deaths than cancer by 2050 if not addressed urgently.
Microbiologists have identified how MRSA may be more effectively treated by modern-day antibiotics, if old-fashioned penicillin is also used. The team from the National University of Ireland Galway and the University of Liverpool have shown that, although penicillin does not kill the bacteria, it does weaken their virulence, making it easier for our immune system and other antibiotics to eradicate the infection. The research findings, funded by the Health Research Board and the Medical Research Council, are published today (15 November 2016) in the Journal of Infectious Diseases.
MRSA infection is caused by a type of Staphylococcal bacteria that has become resistant to many of the antibiotics used to treat ordinary infections. This results in significant morbidity and mortality with up to 20% of patients infected with MRSA dying from systemic infections.
Professor James O’Gara of the National University of Ireland Galway comments: “Our findings explain the anti-virulence mechanism of penicillin-type antibiotics and support the re-introduction of these drugs as an adjunct therapeutic for MRSA infections. MRSA can be extremely virulent, which is part of the challenge in treating it. Our laboratory research shows that when exposed to penicillin, the bacteria switches off its toxin genes and instead concentrates on thickening its cell wall to resist the antibiotic. Our immune systems can then take advantage of this compromised state to destroy the bacteria.”
This new treatment strategy for MRSA infections has the potential to change the current clinical guidelines for treatment of patients with MRSA infections in both hospital and community settings. A recent randomised controlled trial in Australia involving 60 patients led by Menzies School of Health Research showed that the beta-lactam antibiotic flucloxacillin in combination with vancomycin significantly reduced the duration of MRSA sepsis from 3 days to 1.9 days.
“The clinical findings in Australia are very important and now we have the key laboratory data that help explain why the combination of two antibiotics is better than one. The beauty of this approach is that penicillin type antibiotics are not only widely available and safe, but can potentially and more easily be included in clinical practice without the need for long and expensive clinical trials needed for new drugs,” added Professor O’Gara.
Graham Love, Chief Executive at the Health Research Board, commented: “This research demonstrates the potential payback having a vibrant health research programme. It clearly has the potential to change clinical practice and improve outcomes for patients.”
Antimicrobial resistance (AMR) is one of the greatest current threats to human health. The recent report commissioned by the UK Government, concluding that AMR infections will cause more deaths than cancer by 2050 if not addressed urgently.
Study co-lead Professor Aras Kadioglu at the Institute of Infection & Global Health, University of Liverpool added that: “Although aggressive hospital infection control initiatives appear to be having a positive impact on hospital-acquired MRSA rates in some developed countries, the global burden still remains unacceptably high. Infections caused by community associated MRSA strains and strains that are currently methicillin sensitive are increasing at a worrying speed. Given the escalating antimicrobial resistance crisis, it is imperative to identify new therapeutic strategies and to re-evaluate how current antimicrobial drugs are used, as such our data are timely and highly important.”